BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 4, 2022, TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS
Bio-Techne Corporation (NASDAQ: TECH) plans to host a conference call on May 4, 2022, at 8:00 a.m. CDT to discuss its third quarter fiscal 2022 financial results. Interested parties can join via dial-in or webcast, with the details provided in the release. A replay will be available from 11:00 a.m. CDT on May 4 until 11:00 p.m. CDT on June 4. Bio-Techne reported approximately $931 million in net sales for fiscal 2021 and employs around 2,700 staff globally, focusing on high-quality biological products and diagnostic tools.
- None.
- None.
MINNEAPOLIS, April 13, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. CDT to review third quarter fiscal 2022 financial results.
Access to the discussion may be obtained as follows:
Time: | 8:00 a.m. CDT |
Date: | May 4, 2022 |
Dial-in: | 1-877-407-9208 or 1-201-493-6784 (for international callers) |
Conference ID: | 13728915 |
Webcast: |
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13728915.
The replay will be available from 11:00 a.m. CDT on Wednesday, May 4, 2022, until 11:00 p.m. CDT on Saturday, June 4, 2022.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx®Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Contact: David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-may-4-2022-to-announce-third-quarter-2022-financial-results-301520720.html
SOURCE Bio-Techne Corporation
FAQ
What date will Bio-Techne announce its third quarter 2022 financial results?
How can I participate in the Bio-Techne conference call?
When is the replay available for the Bio-Techne conference call?
What is Bio-Techne's revenue for fiscal 2021?
